Sennoside D

Sennoside D at a Glance

Sennoside D is one of the minor dianthrone glycosides of senna, the group of hydroxyanthracene compounds that make the leaf and pod a stimulant laxative. Where the principal markers sennoside A and B are homodianthrones built from two identical rhein-anthrone units, sennoside C and D are heterodianthrones — each built from one rhein-anthrone unit joined to one aloe-emodin anthrone unit — capped with two glucose sugars ^{4Reference 4Nakajima K et al. · 1985AnimalIsolation of a new aloe-emodin dianthrone diglucoside from senna and its potentiating effect on the purgative activity of sennoside A in miceView study →}.

Its role is the same as the rest of the class, and it is a prodrug role. As swallowed, the intact diglucoside is polar, poorly absorbed and pharmacologically inert; it survives the stomach and small intestine, reaches the colon, and is there cleaved by bacterial β-glucosidases and reduced to the active anthrones that stimulate the bowel ^{1,2Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →Reference 2Wang D et al. · 2021Pharmacokinetics of anthraquinones from medicinal plantsView study →}. The molecule that actually does the work is rhein-anthrone, not sennoside D itself.

The honest headline is that sennoside D has essentially no isolate-specific pharmacology. It is quantified and studied collectively, as one of the four senna sennosides (A–D), inside standardised senna — never as a stand-alone drug. There is no human trial, no isolate pharmacokinetic dataset, and no clinical dosing for sennoside D on its own.

Sennoside D vs. Sennoside C

This is the point of the page, because it is the one thing that distinguishes sennoside D from its siblings. The senna sennosides come in stereoisomeric pairs:

• Sennoside A / B — a homodianthrone pair, two rhein-anthrone units joined at the 10,10′ position. Sennoside A is the optically active form; sennoside B is its meso (10,10′-diastereoisomeric) form. These are the principal, pharmacopoeial markers of senna ^{1Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →}.
• Sennoside C / D — a heterodianthrone pair, one rhein-anthrone unit joined to one aloe-emodin anthrone unit. Sennoside C is the optically active form; sennoside D is the corresponding meso stereoisomer — the same A/B relationship, one rung down the abundance ladder ^{4Reference 4Nakajima K et al. · 1985AnimalIsolation of a new aloe-emodin dianthrone diglucoside from senna and its potentiating effect on the purgative activity of sennoside A in miceView study →}.

So sennoside C and D are to each other exactly what sennoside A and B are to each other: a chiral/meso pair of the same heterodianthrone skeleton. Both are minor senna constituents, present at much lower levels than A and B, and both carry the same rhein-anthrone-plus-aloe-emodin-anthrone building blocks.

It is worth stating plainly: the pharmacological evidence here is collective, not isolate-specific. What is established belongs to standardised senna and to the class-defining metabolite rhein-anthrone — measured as total hydroxyanthracene glycosides and expressed as sennoside B. Neither sennoside C nor sennoside D has been separated out and given its own pharmacology, and none is invented for it.

Major Natural Sources

Source	Part	Role of sennoside D
Senna (Senna alexandrina / Cassia angustifolia)	Leaf, pod	Minor heterodianthrone glycoside alongside sennoside A, B and C; part of the hydroxyanthracene-glycoside fraction that defines the laxative 1,4Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →Reference 4Nakajima K et al. · 1985AnimalIsolation of a new aloe-emodin dianthrone diglucoside from senna and its potentiating effect on the purgative activity of sennoside A in miceView study →
Rhubarb (Rheum spp.)	Rhizome/root	Minor sennoside within the anthranoid-glycoside fraction; rhubarb’s principal sennosides are A and B 2Reference 2Wang D et al. · 2021Pharmacokinetics of anthraquinones from medicinal plantsView study →

Pharmacopoeial senna is standardised to total hydroxyanthracene glycosides expressed as sennoside B, not to sennoside D individually — so a clean, source-specific concentration figure for sennoside D is not available here. The unfilled concentration holes are tracked in this compound’s gaps file.

What It's Used For

There is no pharmacology of sennoside D as an isolate. Everything below is the pharmacology of the senna sennoside class and its shared active metabolite, into which sennoside D feeds as one minor prodrug among four.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. The single row below scores the class (standardised senna / the sennosides collectively), because sennoside D has no isolate data of its own — read it as the evidence for the fraction it belongs to, not for the isolated molecule.

01Stimulant laxative (collective, as a senna sennoside)Promising55%Established human use of standardised senna; sennoside D contributes as one minor prodrug of four ^{1,2Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →Reference 2Wang D et al. · 2021Pharmacokinetics of anthraquinones from medicinal plantsView study →}

Mechanisms

Every row is a class/metabolite mechanism, downstream of bacterial activation — none is an action of intact sennoside D itself. The mechanistic detail lives on the rhein-anthrone page.

Pharmacokinetics

There is no isolate pharmacokinetic dataset for sennoside D. By analogy to the characterised sennoside A/B kinetics: the intact diglucoside is polar and poorly absorbed in the upper gut, travels to the colon essentially unchanged, and is metabolised there by gut flora to the anthrones; the aglycone rhein is the species detected in plasma and milk after senna dosing ^{1,2Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →Reference 2Wang D et al. · 2021Pharmacokinetics of anthraquinones from medicinal plantsView study →}. Oral systemic bioavailability of the intact glycoside is low by design — that low absorption is why the laxative action is a colon-local prodrug effect rather than a systemic one.

Clinical Trials

No clinical trial has studied isolated sennoside D. The human evidence is for standardised senna (a well-established stimulant laxative), within which sennoside D is a minor, unquantified marker.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule sits at the far plant end of the isolate-vs-plant spectrum. Nothing is known about isolated sennoside D as a drug — it has not been dosed, tracked or trialled on its own. All the relevant evidence is whole-preparation: the laxative record is for standardised senna, and the mechanism is worked out on the principal sennosides (A/B) and the shared active metabolite rhein-anthrone ^{1,2Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →Reference 2Wang D et al. · 2021Pharmacokinetics of anthraquinones from medicinal plantsView study →}. Sennoside D’s role is assigned by structure and class membership — a minor heterodianthrone prodrug in the sennoside fraction — not by any experiment on the purified compound. Treat every claim here as class-level.

Prevalence in Nature

Sennoside D occurs as a minor dianthrone glycoside of senna (Senna alexandrina / Cassia angustifolia), in both leaf and pod, alongside the principal markers sennoside A and B and its own stereoisomer sennoside C ^{1,4Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →Reference 4Nakajima K et al. · 1985AnimalIsolation of a new aloe-emodin dianthrone diglucoside from senna and its potentiating effect on the purgative activity of sennoside A in miceView study →}. It also appears among the anthranoid glycosides of rhubarb (Rheum spp.), though rhubarb’s dominant sennosides are A and B ^{2Reference 2Wang D et al. · 2021Pharmacokinetics of anthraquinones from medicinal plantsView study →}. In every source it is a low-abundance component: pharmacopoeial senna is standardised to total hydroxyanthracene glycosides (expressed as sennoside B), and the individual level of sennoside D is not separately reported in the sources reviewed here — so its precise concentration and the drivers of its variation (species, plant part, harvest timing) are logged as open gaps for a later pass rather than stated as figures.

Discovery & Synthesis

Sennoside D was characterised among the minor senna sennosides (C and D) during the twentieth-century chemistry of senna glycosides, as the pharmacology of the leaf and pod was resolved from the crude “sennosides” into the discrete stereoisomeric pairs A/B (homodianthrone) and C/D (rhein–aloe-emodin heterodianthrone) ^{4Reference 4Nakajima K et al. · 1985AnimalIsolation of a new aloe-emodin dianthrone diglucoside from senna and its potentiating effect on the purgative activity of sennoside A in miceView study →}. A precise first-isolation date and author for sennoside D specifically are not well documented in the sources reviewed here. Manufacture today is not relevant in the usual sense: sennoside D is not synthesised or produced as an article of commerce — it exists as a minor natural constituent of senna, and human exposure is entirely via standardised senna preparations rather than via any isolated or manufactured sennoside D.

Patents: not yet researched.

Toxicity & Safety

Sennoside D carries a moderate flag — inherited from its class, not from any isolate dataset. As a hydroxyanthracene derivative in the anthranoid stimulant-laxative family, it falls under the same regulatory caution as its relatives: the EFSA panel judged hydroxyanthracene derivatives (including the aloe-emodin and emodin units that these molecules liberate) to show in-vitro genotoxicity and was unable to set a safe intake, and the EU has restricted hydroxyanthracene derivatives in food on that basis ^{3Reference 3EFSA ANS Panel · 2018Safety of hydroxyanthracene derivatives for use in foodView study →}. Set against that, a dedicated review of therapeutic senna use found no convincing evidence that it causes cathartic colon, genotoxicity or carcinogenicity at ordinary laxative doses ^{5Reference 5Morales MA et al. · 2009Is senna laxative use associated with cathartic colon, genotoxicity, or carcinogenicity? Journal of Toxicology. https://pubmed.ncbi.nlm.nih.gov/20107583/View study →} — so the class concern is real but its magnitude at normal intakes is debated. Stimulant-laxative cautions (electrolyte loss, cramping, dependence with chronic misuse) apply to the whole senna preparation, not to sennoside D as an isolate.

Pregnancy note (prose only). Anthranoid stimulant laxatives are generally cautioned in pregnancy and lactation at the preparation level; the aglycone rhein is detectable in breast milk after senna dosing ^{1,2Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →Reference 2Wang D et al. · 2021Pharmacokinetics of anthraquinones from medicinal plantsView study →}. That decision belongs to the senna herb page and the product where intake is decided, not to this molecule-level page. No isolate reproductive-toxicity dataset exists for sennoside D.

Safety at a Glance

⚠️ Moderate toxicity

• An inert prodrug glycoside. As swallowed, sennoside D is poorly absorbed and pharmacologically inactive until colonic bacteria activate it — there is no direct systemic drug action to weigh.
• Hydroxyanthracene-class restriction. It belongs to the anthranoid/hydroxyanthracene family that EFSA flagged for in-vitro genotoxicity (via the emodin/aloe-emodin units) and that the EU has restricted in food; treat class-level laxative cautions as applying.
• Stimulant-laxative cautions apply to the preparation. Electrolyte loss, cramping and dependence come with chronic senna misuse — decided at the herb/product level, not for isolated sennoside D.
• Pregnancy/lactation is a preparation-level decision. Anthranoid laxatives are cautioned in pregnancy; rhein reaches breast milk. See the senna herb page.

Dosage

There is no dose for isolated sennoside D — it is a minor, inert prodrug marker, not a dosed drug. Human exposure is entirely indirect, via standardised senna preparations dosed to their total hydroxyanthracene-glycoside content (expressed as sennoside B); a common OTC adult range is roughly 15–30 mg sennosides/day ^{1Reference 1Le J et al. · 2021Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compoundView study →}. These are figures for the parent preparation and are not a personal recommendation.

References

1. Le J, Ji H, Zhou X, et al. (2021). Pharmacology, toxicology, and metabolism of sennoside A, a medicinal plant-derived natural compound. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/34764866/
2. Wang D, Wang XH, Yu X, et al. (2021). Pharmacokinetics of anthraquinones from medicinal plants. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/33935728/
3. EFSA ANS Panel (2018). Safety of hydroxyanthracene derivatives for use in food. EFSA Journal. https://pubmed.ncbi.nlm.nih.gov/32625659/
4. Nakajima K, Yamauchi K, Kuwano S (1985). Isolation of a new aloe-emodin dianthrone diglucoside from senna and its potentiating effect on the purgative activity of sennoside A in mice. Journal of Pharmacy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/2867138/
5. Morales MA, Hernández D, Bustamante S, et al. (2009). Is senna laxative use associated with cathartic colon, genotoxicity, or carcinogenicity? Journal of Toxicology. https://pubmed.ncbi.nlm.nih.gov/20107583/